Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 5/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HGF | P14210 | 1/20 | 0.40 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917605 | 0.96 | CYP11B1 (0.47) | GRK2S1PR5MAPK14GRK1CYP11B1 | |
| SCHEMBL3105830 | 0.95 | CYP11B1 (0.44) | GRK2S1PR5MAPK14GRK1CYP11B1 | |
| SCHEMBL3912908 | 0.94 | MAPK14 (0.43) | GRK2S1PR5MAPK14GRK1ERN1 | |
| SCHEMBL3915748 | 0.94 | GRK2 (0.41) | GRK2S1PR5MAPK14GRK1ERN1 | |
| SCHEMBL3916324 | 0.93 | SMN1; SMN2 (0.44) | GRK2S1PR5MAPK14CTSA | |
| SCHEMBL3913900 | 0.92 | RXRA (0.43) | GRK2S1PR5MAPK14GRK1PTPN2 | |
| SCHEMBL3923475 | 0.92 | S1PR5 (0.47) | GRK2S1PR5MAPK14GRK1PTPN2 | |
| SCHEMBL3914313 | 0.92 | S1PR5 (0.41) | GRK2S1PR5MAPK14GRK1ERN1 | |
| SCHEMBL3923436 | 0.91 | S1PR5 (0.42) | GRK2S1PR5MAPK14ERN1PTPN2 | |
| SCHEMBL3922800 | 0.91 | MRGPRX4 (0.40) | GRK2S1PR5MAPK14GRK1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | GRK2 173/4885S1PR5 2995/4885MAPK14 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.